JP7388636B2 - 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物 - Google Patents

結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物 Download PDF

Info

Publication number
JP7388636B2
JP7388636B2 JP2020566323A JP2020566323A JP7388636B2 JP 7388636 B2 JP7388636 B2 JP 7388636B2 JP 2020566323 A JP2020566323 A JP 2020566323A JP 2020566323 A JP2020566323 A JP 2020566323A JP 7388636 B2 JP7388636 B2 JP 7388636B2
Authority
JP
Japan
Prior art keywords
tuberculosis
mtbvac
strain
composition
cfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020566323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514392A (ja
JP2021514392A5 (https=
Inventor
モンタニェス カルロス マルティン
アネント フアン イグナシオ アギロ
アセンシオ ヘスス アンヘル ゴンサロ
デシスラバ ヴァネバ マリノバ
マイス サンティアゴ ウガンダ
サンチェス エステバン ロドリゲス
コロラド エウヘニア プエンテス
アルバレス－サントゥラーノ コンセプシオン フェルナンデス
Original Assignee
ウニベルシダッド デ サラゴサ
ビオファブリ エセ．エレ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシダッド デ サラゴサ, ビオファブリ エセ．エレ． filed Critical ウニベルシダッド デ サラゴサ
Publication of JP2021514392A publication Critical patent/JP2021514392A/ja
Publication of JP2021514392A5 publication Critical patent/JP2021514392A5/ja
Priority to JP2023118940A priority Critical patent/JP2023153868A/ja
Application granted granted Critical
Publication of JP7388636B2 publication Critical patent/JP7388636B2/ja
Priority to JP2025122753A priority patent/JP2025160294A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/16—Magnesium; Mg chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/35—Polyols, e.g. glycerin, inositol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020566323A 2018-02-19 2019-02-19 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物 Active JP7388636B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023118940A JP2023153868A (ja) 2018-02-19 2023-07-21 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物
JP2025122753A JP2025160294A (ja) 2018-02-19 2025-07-22 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382097 2018-02-19
EP18382097.6 2018-02-19
PCT/EP2019/054106 WO2019158779A1 (en) 2018-02-19 2019-02-19 Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023118940A Division JP2023153868A (ja) 2018-02-19 2023-07-21 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物

Publications (3)

Publication Number Publication Date
JP2021514392A JP2021514392A (ja) 2021-06-10
JP2021514392A5 JP2021514392A5 (https=) 2022-03-02
JP7388636B2 true JP7388636B2 (ja) 2023-11-29

Family

ID=61557215

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020566323A Active JP7388636B2 (ja) 2018-02-19 2019-02-19 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物
JP2023118940A Pending JP2023153868A (ja) 2018-02-19 2023-07-21 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物
JP2025122753A Pending JP2025160294A (ja) 2018-02-19 2025-07-22 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023118940A Pending JP2023153868A (ja) 2018-02-19 2023-07-21 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物
JP2025122753A Pending JP2025160294A (ja) 2018-02-19 2025-07-22 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物

Country Status (9)

Country Link
US (3) US11826411B2 (https=)
EP (2) EP3755374B1 (https=)
JP (3) JP7388636B2 (https=)
CN (2) CN116751703A (https=)
AU (2) AU2019221709B2 (https=)
BR (1) BR112020016704A2 (https=)
CA (1) CA3091304A1 (https=)
ES (1) ES2967066T3 (https=)
WO (1) WO2019158779A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria
CN113122484B (zh) * 2021-06-03 2023-11-03 郑州安图生物工程股份有限公司 一种非结核分枝杆菌的冻干保护剂及其制备方法和保藏方法
WO2025063217A1 (ja) 2023-09-20 2025-03-27 住友金属鉱山株式会社 赤外線吸収粒子、赤外線吸収粒子分散液、赤外線吸収透明基材、赤外線吸収粒子分散体、赤外線吸収合わせ透明基材

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108956A (en) * 1964-05-26 1968-04-10 Ciba Ltd Process for the manufacture of bcg vaccines
BR9808441A (pt) * 1997-03-28 2000-05-23 Cytoclonal Pharmaceutics Inc Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
BRPI0709106B8 (pt) * 2006-03-24 2021-05-25 Univ Zaragoza vacina contra tuberculose
CN104324365B (zh) * 2014-10-24 2016-03-16 孙二琳 重组人干扰素-α-2b-BCG的干粉剂制备方法
ES2615512B1 (es) 2015-11-06 2018-03-15 Universidad De Zaragoza Dispositivo y sistema microfluídico para el estudio de cultivos celulares
ES2626237B1 (es) 2015-12-22 2018-05-03 Universidad De Zaragoza Sistema electrónico de potencia modular variable para la generación de pulsos eléctricos y usos asociados
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
ES2679721B1 (es) 2017-01-18 2019-06-21 Univ Zaragoza Generador de aerosoles nanoparticulados y procedimiento de generacion de aerosoles en continuo asociado a dicho generador
ES2738926A1 (es) 2018-07-26 2020-01-27 Univ Zaragoza Granulisina, metodo de obtencion y usos

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ainhoa ARBUES et al.，"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials"，Vaccine，2013年10月，Vol. 31, No. 42，p.4867-4873，DOI: 10.1016/j.vaccine.2013.07.051
Dessislava MARINOVA et al.，"MTBVAC from discovery to clinical trials in tuberculosis-endemic countries"，Expert Review of Vaccines，2017年05月12日，Vol. 16, No. 6，p.565-576，DOI: 10.1080/14760584.2017.1324303
Jpn. J. Infect. Dis.，2007年，60，331-336

Also Published As

Publication number Publication date
CA3091304A1 (en) 2019-08-22
AU2019221709B2 (en) 2024-04-18
JP2021514392A (ja) 2021-06-10
EP3755374B1 (en) 2023-11-15
EP4233912A3 (en) 2023-11-01
US20240382575A1 (en) 2024-11-21
WO2019158779A1 (en) 2019-08-22
AU2019221709A1 (en) 2020-10-15
US20230165948A1 (en) 2023-06-01
CN112449604B (zh) 2023-05-26
AU2024203034A1 (en) 2024-05-30
EP4233912A2 (en) 2023-08-30
EP3755374A1 (en) 2020-12-30
ES2967066T3 (es) 2024-04-25
EP3755374C0 (en) 2023-11-15
RU2020130786A (ru) 2022-03-21
CN112449604A (zh) 2021-03-05
BR112020016704A2 (pt) 2020-12-15
US11826411B2 (en) 2023-11-28
JP2025160294A (ja) 2025-10-22
CN116751703A (zh) 2023-09-15
JP2023153868A (ja) 2023-10-18
US20230330201A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
JP2023153868A (ja) 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物
KR100202771B1 (ko) 미생물감염에대한숙주의예방적치료용백신
CN1360594A (zh) 用于治疗感染的减毒微生物
KR20100065243A (ko) 마이코박테리움의 일렉트로포레이션 및 마이코박테리아에서의 항원의 과발현
JP5461776B2 (ja) マイコバクテリウムのエレクトロポレーションおよびマイコバクテリア中における抗原類の過剰発現
US8642011B2 (en) Tuberculosis vaccine
US7722861B2 (en) Attenuated Mycobacterium tuberculosis vaccines
JP6229080B2 (ja) 新規な温度敏感性マイコバクテリア菌株を含むマイコバクテリア感染症に対するワクチン組成物
CN114272364A (zh) 一种结核分枝杆菌串联dna疫苗w541及其制备方法与应用
Hernandez-Pando et al. Recombinant BCG vaccine candidates
RU2778094C2 (ru) Композиции для применения в качестве профилактического средства для пациентов с риском туберкулезной инфекции или в качестве вторичных средств для лечения пациентов с туберкулезной инфекцией
ES2549366B1 (es) TRIPLE MUTANTE DEL COMPLEJO MYCOBACTERIUM TUBERCULOSIS erp-, phoP- y DIM-
EP1164188A1 (en) Auxotrophic Mycobacterium mutants and tuberculosis vaccine
US20100284963A1 (en) Growth regulatable recombinant bcg immunogenic compositions
CA2298063A1 (fr) Souches de mycobacterium dont le gene erp est modifie et composition vaccinale la contenant
WO1999029342A1 (en) Vaccines containing attenuated bacteria
Torracinta et al. New Vaccine Strategies to Improve, Boost, or Replace BCG
Levine et al. Attenuated strains of Salmonella enterica serovars Typhi and Paratyphi as live oral vaccines against enteric fever
JP2022550722A (ja) 弱毒生マイコバクテリアの肺送達による治療有効性
Heiat et al. Construction and immunogenicity of a genetically mutant of a native Shigella dysenteriae type 1 isolated from an Iranian patient with diarrhea by recombineering

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231107

R150 Certificate of patent or registration of utility model

Ref document number: 7388636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150